Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alba A Brandes

Showing results (151-160 of 178) with videos related to

Pageof 18
Sort By:
Neurology|May 12, 2019
Imaging necrosis during treatment is associated with worse survival in EORTC 26101 studyMartha Nowosielski, Thierry Gorlia, Jacoline E C Bromberg, et al.
Neuro-Oncology Advances|January 7, 2021
Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modelingMarijke B Coomans, Linda Dirven, Neil K Aaronson, et al.
The Lancet. Oncology|April 18, 2015
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trialSandro Pignata, Domenica Lorusso, Giovanni Scambia, et al.
International Journal of Molecular Sciences|May 9, 2017
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and LomustineDavid Capper, Andreas von Deimling, Alba A Brandes, et al.
Acta Neuropathologica|January 26, 2018
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033Pierre Bady, Sebastian Kurscheid, Mauro Delorenzi, et al.
The New England Journal of Medicine|November 16, 2017
Lomustine and Bevacizumab in Progressive GlioblastomaWolfgang Wick, Thierry Gorlia, Martin Bendszus, et al.
Neuro-Oncology|April 29, 2017
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteriaLakshmi Nayak, Lisa M DeAngelis, Alba A Brandes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2012
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951Martin J van den Bent, Alba A Brandes, Martin J B Taphoorn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2022
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial TumorsAndrew B Lassman, Khê Hoang-Xuan, Mei-Yin C Polley, et al.
The Lancet. Oncology|October 1, 2016
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyJaap C Reijneveld, Martin J B Taphoorn, Corneel Coens, et al.
Pageof 18

Showing results (151-160 of 178) with videos related to

Sort By:
Pageof 18
Neurology|May 12, 2019
Imaging necrosis during treatment is associated with worse survival in EORTC 26101 studyMartha Nowosielski, Thierry Gorlia, Jacoline E C Bromberg, et al.
Neuro-Oncology Advances|January 7, 2021
Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modelingMarijke B Coomans, Linda Dirven, Neil K Aaronson, et al.
The Lancet. Oncology|April 18, 2015
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trialSandro Pignata, Domenica Lorusso, Giovanni Scambia, et al.
International Journal of Molecular Sciences|May 9, 2017
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and LomustineDavid Capper, Andreas von Deimling, Alba A Brandes, et al.
Acta Neuropathologica|January 26, 2018
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033Pierre Bady, Sebastian Kurscheid, Mauro Delorenzi, et al.
The New England Journal of Medicine|November 16, 2017
Lomustine and Bevacizumab in Progressive GlioblastomaWolfgang Wick, Thierry Gorlia, Martin Bendszus, et al.
Neuro-Oncology|April 29, 2017
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteriaLakshmi Nayak, Lisa M DeAngelis, Alba A Brandes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2012
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951Martin J van den Bent, Alba A Brandes, Martin J B Taphoorn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2022
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial TumorsAndrew B Lassman, Khê Hoang-Xuan, Mei-Yin C Polley, et al.
The Lancet. Oncology|October 1, 2016
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyJaap C Reijneveld, Martin J B Taphoorn, Corneel Coens, et al.
Pageof 18